Ultragenyx Pharmaceutical | RARE - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 1.11B 52.78M 2026-09
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
BioMarin Pharmaceutical USD 819.04M 5.5B 2026-09
Immunic USD 23.33M 2.67M 2025-12
Insmed USD 606.26M 79.46M 2026-09
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
Kyowa Hakko Kirin JPY 94.9B 28B 2026-09
MacroGenics USD 42.87M 21.68M 2026-06
Moderna USD 960M 817M 2026-06
Neurocrine Biosciences USD 779.7M 40.6M 2026-09
PTC Therapeutics USD 211.54M 15.12M 2026-06
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Ultragenyx Pharmaceutical USD 283M 6M 2026-09
Vertex Pharmaceuticals USD 2.18B 118.2M 2026-09